Trevi Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Trevi Therapeutics, Inc. (TRVI) on June 30, 2020, reporting events occurring on June 29, 2020. The Company is a Delaware corporation headquartered in New Haven, Connecticut, and its common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
The primary material change reported is the election of Dominick C. Colangelo to the Board of Directors as a Class II Director, effective June 29, 2020. His term expires at the 2021 annual meeting of stockholders. Mr. Colangelo was also appointed to the Audit Committee, which now consists of Mr. Colangelo, Michael Heffernan, and Anne VanLent (Chair).
Compensation and Governance Details
- Cash Retainers: Mr. Colangelo will receive an annual cash retainer of $35,000 for Board service and $7,500 for Audit Committee service, payable quarterly in arrears.
- Equity Grant: Upon election, Mr. Colangelo was granted an option to purchase 23,684 shares of common stock at an exercise price of $6.87 per share.
- Vesting Schedule: 50% of the option vests on the earlier of the first anniversary of the grant date or the first annual meeting following the grant; the remainder vests on the earlier of the second anniversary or the second annual meeting. The option becomes fully exercisable upon a change in control.
- Indemnification: Mr. Colangelo entered into the Company's standard indemnification agreement, potentially requiring the Company to cover expenses, judgments, fines, and settlements related to his service as a director.
Outlook and Risks
The filing does not provide updated business guidance, outlook, or specific risk factors beyond the standard indemnification obligations associated with the new director appointment.
Key Facts for Investor Verification
- Verify the impact of the new Audit Committee composition on the Company's financial oversight.
- Review the dilution impact of the 23,684 share option grant at the $6.87 exercise price.
- Confirm Mr. Colangelo's background and potential conflicts of interest given his prior executive roles at Vericel Corporation and Eli Lilly.
- Check subsequent filings for the Company's cash position and burn rate, as this 8-K does not provide liquidity data.